Home
About CanImGuide
Technology
Contact
News

Nils Siegbahn CanimGuide

16th March 2020Malin Bergholm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Save my name and email in this browser for the next time I comment.

Recent Posts

New discoveries in cancer related immunosuppression are paving the way for an entirely new immunotherapeutic strategy.
CanImGuide Initiates Clinical Development of New Treatment in Cancer
The Nobel Prize in Medicine puts the spotlight on CanImGuide’s focus area Immunology.
CanimGuide appoints new CEO

What we do

CanimGuide is a company with a novel, simple but sophisticated and highly innovative, peptide approach to immuno-oncology.

Pages

Home
About CanImGuide
Technology
Contact
News

Recent Posts

New discoveries in cancer related immunosuppression are paving the way for an entirely new immunotherapeutic strategy. 28th November 2018
CanImGuide Initiates Clinical Development of New Treatment in Cancer 11th October 2018
The Nobel Prize in Medicine puts the spotlight on CanImGuide’s focus area Immunology. 5th October 2018
CanimGuide appoints new CEO 26th June 2018

CanImGuide Therapeutics AB Scheelevägen 2, 223 81 Lund, Sweden

info@canimguide.com

+46 730 870 660

© 2020 All rights reserved. CanimGuide Therapeutics AB

Menu